These findings were corroborated by a 2021 case report of a 2-year-old boy with TBL1XR1-RARB APL, where initial ATRA/RIF therapy achieved transient remission, but subsequent AML-style chemotherapy (FLAG-IDA) and targeted maintenance ensured durable remission (15). Here, RARB is linked to acute myeloid leukemia.